Landmark diabetes trials like the UK PDS have taught us that early and intensive HbA1c control helps reduce the risk of developing complications in type 2 diabetes. However, sustained glycaemic control in people with type 2 diabetes can be difficult to achieve.
Despite the recent advances, there is still a significant gap in optimum type 2 diabetes management, which is evident from the fact that almost 50% of our type 2 diabetes patients are still not at their individualised HbA1c targets, and an even larger proportion are either obese or overweight.
In this interview discuss the key clinical insights from the manuscript titled ‘Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a first-in-class twincretin’ published in Diabetes therapy.
GP, Platinum Medical Centre, Chermside, Brisbane.
GP, Brisbane, & Chair of the RACGP Diabetes Specific Interests Committee.
Supported by: This interview was supported by Eli Lilly Australia, Level 9, 60 Margaret Street, Sydney, NSW, 2000. Produced Feb 2024.
Tap the share icon 
and select 'Add to Home Screen' to add the site to your home screen for quick access!
Access private podcast